Home » Reports » Broker Ratings » AstraZeneca plc 7.9% Potential Upside Indicated by Barclays Capital
broker ratings

AstraZeneca plc 7.9% Potential Upside Indicated by Barclays Capital

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ this morning by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 6600 GBX on its stock. This now indicates the analyst believes there is a possible upside of 7.9% from today’s opening price of 6118 GBX. Over the last 30 and 90 trading days the company share price has increased 416 points and increased 67 points respectively. The 52 week high share price is 6196 GBX while the year low stock price is currently 4544.5 GBX.

AstraZeneca plc has a 50 day moving average of 5,852.60 GBX and the 200 Day Moving Average price is recorded at 5,430.17. There are currently 1,266,798,130 shares in issue with the average daily volume traded being 2,506,213. Market capitalisation for LON:AZN is £77,642,057,326 GBP.